WO2023062170A3 - Adjuvants - Google Patents

Adjuvants Download PDF

Info

Publication number
WO2023062170A3
WO2023062170A3 PCT/EP2022/078592 EP2022078592W WO2023062170A3 WO 2023062170 A3 WO2023062170 A3 WO 2023062170A3 EP 2022078592 W EP2022078592 W EP 2022078592W WO 2023062170 A3 WO2023062170 A3 WO 2023062170A3
Authority
WO
WIPO (PCT)
Prior art keywords
polysorbate
adjuvants
octoxynol
mannose
histidine
Prior art date
Application number
PCT/EP2022/078592
Other languages
French (fr)
Other versions
WO2023062170A2 (en
Inventor
Francesco Doro
Donatello Laera
Malte Meppen
Arianna RAPONI
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204323.6A external-priority patent/GB202204323D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of WO2023062170A2 publication Critical patent/WO2023062170A2/en
Publication of WO2023062170A3 publication Critical patent/WO2023062170A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)

Abstract

The present invention relates inter alia to particles comprising aluminium hydroxide and (a) a stabilising excipient selected from the list consisting of: octoxynol-9, polysorbate 20, polysorbate 80, sucrose, mannose, polyvinylpyrrolidone and glycine; and/or (b) histidine.
PCT/EP2022/078592 2021-10-15 2022-10-13 Adjuvants WO2023062170A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21202844.3 2021-10-15
EP21202844 2021-10-15
GBGB2204323.6A GB202204323D0 (en) 2022-03-28 2022-03-28 Adjuvants
GB2204323.6 2022-03-28

Publications (2)

Publication Number Publication Date
WO2023062170A2 WO2023062170A2 (en) 2023-04-20
WO2023062170A3 true WO2023062170A3 (en) 2023-05-25

Family

ID=84359541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/078592 WO2023062170A2 (en) 2021-10-15 2022-10-13 Adjuvants

Country Status (1)

Country Link
WO (1) WO2023062170A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021152A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
US20050158334A1 (en) * 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021152A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
US20050158334A1 (en) * 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARM HOGENESCH ET AL: "Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want", NPJ VACCINES, vol. 3, no. 1, 10 October 2018 (2018-10-10), pages 1 - 11, XP055707450, DOI: 10.1038/s41541-018-0089-x *
VRIELING HILDE ET AL: "Stabilised aluminium phosphate nanoparticles used as vaccine adjuvant", COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 181, 1 September 2019 (2019-09-01), NL, pages 648 - 656, XP093018850, ISSN: 0927-7765, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S092777651930428X/pdfft?md5=91c3e3b19d5f3172210331a4648e8c02&pid=1-s2.0-S092777651930428X-main.pdf> DOI: 10.1016/j.colsurfb.2019.06.024 *
XINRAN LI ET AL: "Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles", JOURNAL OF CONTROLLED RELEASE, vol. 173, 1 January 2014 (2014-01-01), AMSTERDAM, NL, pages 148 - 157, XP055510346, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2013.10.032 *

Also Published As

Publication number Publication date
WO2023062170A2 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
WO2002102829A3 (en) Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2534625A1 (en) Infection prophylaxis using immune response modifier compounds
WO2000047222A3 (en) Inactivated influenza virus vaccine for nasal or oral administration
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MXPA02011415A (en) Chimeric arterivirus like particles.
WO2020157222A8 (en) Inactivated apxia, apxiia and apxiiia toxins
CA3139411A1 (en) Novel peptide compound or pharmaceutically acceptable salt thereof
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2021178714A3 (en) ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
WO2023062170A3 (en) Adjuvants
WO2002004495A3 (en) Streptococcus pyogenes antigen
WO2022032073A3 (en) Trpml modulators
WO2021195596A3 (en) Reverse genetic system for sars-cov-2
WO2021086145A3 (en) Rice cake comprising allulose, and preparation method therefor
WO2020201644A3 (en) High-lift device
WO2019191586A3 (en) Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof
WO2023019174A3 (en) Antibodies to sars-cov-2
EP4164686A4 (en) Rsv vaccine compositions, methods, and uses thereof
EP4110906A4 (en) Novel systems, methods, and compositions for the glycosylation of cannabinoid compounds
MX2022001071A (en) Methods and compositions for controlling or reducing pests.
WO2020181052A3 (en) Systems and methods for providing illumination
WO2022254200A8 (en) Peptide screen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22805794

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE